Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)

Université de Montréal

$100,000.00

Molecular mechanisms of antifungal drug resistance in Candida albicans

EF 2008-09

Résumé
The fungus Candida albicans is one of the most commonly encountered human pathogens. It causes a wide variety of infections, ranging from mucosal infections in healthy individuals to life-threatening systemic infections in individuals with an impaired immune system. The drugs most widely used for the treatment of candidosis are azoles. However, treatment failure due to the emergence of azole-resistant strains of C. albicans in patients receiving long-term therapy, such as AIDS patients, is a serious medical problem. It has been shown that azole-resistant C. albicans strains overexpress transporter proteins that pump azoles out of the cells, preventing the drugs from inhibiting cell growth. This is because C. albicans azole-resistant cells have acquired activating mutations in proteins called transcription factors. Our research project use genetic, genomic, molecular biology and biochemical approaches and is aimed at better understanding the function of these multidrug transporters and their transcriptional regulators in the response of C. albicans cells to drugs and to oxidative stress. The results from our studies will help to better understand the molecular mechanisms of azole resistance with the aim of circumventing or preventing it. Our studies will also contribute to a better knowledge of the biology of this and other clinically important fungi.
Programme
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
183459
Name
Raymond Martine
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Microbiology & Infectious Diseases
Projecttitle
Molecular mechanisms of antifungal drug resistance in Candida albicans
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - Priority Announcement: Infection and Immunity (Bridge Funding)
Keyworddelim
Abc Transporters; Azole Drugs; Candida Albicans; Dna Microarrays; Multidrug Resistance; Transcription Factors
Abstract
The fungus Candida albicans is one of the most commonly encountered human pathogens. It causes a wide variety of infections, ranging from mucosal infections in healthy individuals to life-threatening systemic infections in individuals with an impaired immune system. The drugs most widely used for the treatment of candidosis are azoles. However, treatment failure due to the emergence of azole-resistant strains of C. albicans in patients receiving long-term therapy, such as AIDS patients, is a serious medical problem. It has been shown that azole-resistant C. albicans strains overexpress transporter proteins that pump azoles out of the cells, preventing the drugs from inhibiting cell growth. This is because C. albicans azole-resistant cells have acquired activating mutations in proteins called transcription factors. Our research project use genetic, genomic, molecular biology and biochemical approaches and is aimed at better understanding the function of these multidrug transporters and their transcriptional regulators in the response of C. albicans cells to drugs and to oxidative stress. The results from our studies will help to better understand the molecular mechanisms of azole resistance with the aim of circumventing or preventing it. Our studies will also contribute to a better knowledge of the biology of this and other clinically important fungi.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Raymond, Martine
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~